JAGUAR HEALTH, INC. Payments of Financing Costs
JAGUAR HEALTH, INC. (JAGX) reported Payments of Financing Costs of $640.00 thousand for the 9-month period ending 2021-09-30, per its 10-Q filed 2021-11-17.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfFinancingCosts · last filed 2022-03-11
- JAGUAR HEALTH, INC. payments of financing costs for the quarter ending 2021-09-30 was $309.00K, a 0.00% change year-over-year.
- JAGUAR HEALTH, INC. payments of financing costs for the quarter ending 2021-06-30 was -$1.18M.
- JAGUAR HEALTH, INC. payments of financing costs for the quarter ending 2021-03-31 was $1.51M.
- JAGUAR HEALTH, INC. payments of financing costs for the quarter ending 2020-12-31 was $0.00.
- JAGUAR HEALTH, INC. payments of financing costs for fiscal 2020 was $640.00K.
| Period end | Payments of Financing Costs 3 month | Payments of Financing Costs 6 month | Payments of Financing Costs 9 month | Payments of Financing Costs 12 month |
|---|---|---|---|---|
| 2021-09-30 | $309.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-17 | -$874.00K derived: sum of 2 quarters · filed 2021-11-17 | $640.00K 10-Q · filed 2021-11-17 | $640.00K derived: sum of 4 quarters · filed 2022-03-11 |
| 2021-06-30 | -$1.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $331.00K 10-Q · filed 2021-08-13 | $331.00K derived: sum of 3 quarters · filed 2022-03-11 | $640.00K derived: sum of 4 quarters · filed 2022-03-11 |
| 2021-03-31 | $1.51M 10-Q · filed 2021-05-17 | $1.51M derived: sum of 2 quarters · filed 2022-03-11 | $1.82M derived: sum of 3 quarters · filed 2022-03-11 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $309.00K derived: sum of 2 quarters · filed 2022-03-11 | $640.00K 10-K · filed 2022-03-11 | |
| 2020-09-30 | $309.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16 | $640.00K 10-Q · filed 2020-11-16 | ||
| 2020-06-30 | $331.00K 10-Q · filed 2020-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |